Abstract 4218
Background
EGFR- mut NSCLC patients benefit from EGFR-TKIs therapy. However, most patients relapse within 1 to 2 years. In 40-60% of the cases, the mechanism of resistance is the emergence of the EGFR p.T790M mutation, and third generation TKIs have shown efficacy in this setting. The availability of new biopsies at relapse to TKIs is limited and guidelines recommend testing for the p.T790M in blood at relapse to TKIs, and rebiopsy only in case of a negative result. Several blood based methodologies for EGFR-mut detection have been developed, including some NGS approaches, but comparison studies are limited. We aim to evaluate the agreement, specificity and sensitivity of methodologies available for T790M testing in liquid biopsies and to determine the best pre-analytical conditions for T790M mutation identification.
Trial design
The RING is a non-PAS, non-interventional, cross-sectional, diagnostic study that will enroll 75 patients from different Spanish institutions. Blood samples will be collected at the time of progression to first and second generation TKIs, and sent to the laboratories participating in the study. Three DNA extraction procedures will be tested; Maxwell® RSC cfDNA (Promega), the QIAamp® Circulating Nucleic Acid Kit (Qiagen) and automatic extraction using Qiasymphony® (Qiagen). The presence of the p.T790M in the purified DNA will be tested by 7 methodologies, namely cobas® EGFR Mutation Test v2 (Roche Diagnostics), Therascreen EGFR Plasma RGQ PCR Kit (Qiagen), QuantStudio® 3D Digital PCR System (Applied Biosystems), a 5′-nuclease real-time PCR (Taqman®) assay in presence of PNA, BEAMing digital PCR (Sysmex Inostics), NGS with the Oncomine® panel for Ion Torrent (Thermofisher) and NGS with the Lung Cancer Panel for GeneReader® (Qiagen). The kappa coefficient values and its corresponding 95% confidence intervals (95% CI) will be used to assess the agreement between methodologies and the Intraclass Correlation Coefficients (ICC) and Bland & Altman plots to evaluate the concordance between quantitative methodologies. Finally, we calculate that 40 patients will have a re-biopsy mutation T790M analysis, which will be considered the gold standard to estimate the sensitivity and specificity of each method.
Clinical trial identification
Legal entity responsible for the study
Spanish Lung Cancer Group / Grupo Español de Cancer de Pulmon (Slcg/Gecp).
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract